Orexo presents positive study results for Sublinox™ (OX 22) at APSS (Associated Professional Sleep Societies)

Orexo presents positive study result for Sublinox™ (OX 22) at APSS (Associated Professional Sleep Societies) in Salt Lake City, USA. The results from the Sublinox (OX 22) study demonstrates fast onset of sleep, and maintained sleep during the night without “day-after” residual effects. The study – involving 21 healthy volunteers aged 18-40 years – was presented on June 21, 2006 at APSS (Associated Professional Sleep Societies) in Salt Lake City, USA. Sublinox™ (OX 22) is based on the well-documented substance zolpidem using Orexo´s sublingual technology, involving a tablet placed under the tongue for fast and effective uptake of the active substance over the sublingual mucosa. The result shows that Sublinox™ (OX 22) reduce the time to sleep onset by 30 procent compared to a conventional oral zolpidem tablet. “The study confirms previous results and shows that Sublinox™ (OX 22), in addition to fast sleep induction, offers patients with sleeping disturbances good and maintained sleep without “day-after”- residual effects. In all, this gives Sublinox™ (OX 22) a competitive advantage in comparison with excisting drugs, where time to sleep is longer and more unpredictable” said Zsolt Lavotha, President and CEO of Orexo AB. Orexo initiates Phase III studies during 2006 to further document Sublinox™ (OX 22) unique clinical profile in preparation for registration and out-licensing. The phase III programme is expected to be completed in the first half of 2007 followed by registration application for the US and the EU during the second half of 2007. For further information, please contact: Zsolt Lavotha, President and CEO, Orexo AB Tel: +46-18-780 88 12, e-mail: zsolt.lavotha@orexo.se Claes Wenthzel, Executive Vice President and CFO, Orexo AB Tel: +46-18-780 88 44, e-mail: claes.wenthzel@orexo.se Thomas Lundqvist, Executive Vice President and CSO, Orexo AB Tel: +46-18-780 88 04. e-mail: thomas.lundqvist@orexo.se